Cyanosis Due to Methemoglobinemia Induced by Topical Anesthesia in a Premature Infant
Background: Methemoglobinemia is a rare cause of cyanosis in pediatric patients and may arise as a result of a genetic defect in red blood cell metabolism or hemoglobin structure, or it may be acquired following exposure to various oxidant drugs or toxins. It is characterized by increased quantities of hemoglobin in which the iron of heme is oxidized to the ferric (Fe3+) form. Case Report: We describe a case of a premature infant who developed cyanosis after dermal application of 1 gram of a eutectic mixture of lidocaine 2.5% and prilocaine 2.5% ointment before the insertion of a central venous catheter for parenteral nutrition. Eight hours after dermal application, his methemoglobin levels were 24.6% and was given an intravenous methylene blue infusion which promptly cleared his cyanosis and restored tissue oxygenation. The samples were analyzed for methemoglobin reductase enzyme activity. The initial enzyme activity level was 14.8 IU/g. Seven months later, the activity level of methemoglobin reductase was repeated and resulted normal (25.7 IU/g). Conclusion: We conclude that a light inadvertent miscalculation of the dose can lead to serious adverse effect, such as in our case. Because preterm neonates are easily overdosed for low weight routinely use of EMLA should be carefully evaluated..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Current drug therapy - 12(2017), 1, Seite 73-76 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Georgios Eleftheriou [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1995566853 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1995566853 | ||
| 003 | DE-627 | ||
| 005 | 20230517050058.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1995566853 | ||
| 035 | |a (DE-599)GBVOLC1995566853 | ||
| 035 | |a (PRQ)benthamscience_primary_http_www_eurekaselect_com_openurl_content_php_genre_article_issn_1574_8855_volume_12_issue_1_spage_730 | ||
| 035 | |a (KEY)0598958220170000012000100073cyanosisduetomethemoglobinemiainducedbytopicalanes | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 100 | 0 | |a Georgios Eleftheriou |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cyanosis Due to Methemoglobinemia Induced by Topical Anesthesia in a Premature Infant |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Background: Methemoglobinemia is a rare cause of cyanosis in pediatric patients and may arise as a result of a genetic defect in red blood cell metabolism or hemoglobin structure, or it may be acquired following exposure to various oxidant drugs or toxins. It is characterized by increased quantities of hemoglobin in which the iron of heme is oxidized to the ferric (Fe3+) form. Case Report: We describe a case of a premature infant who developed cyanosis after dermal application of 1 gram of a eutectic mixture of lidocaine 2.5% and prilocaine 2.5% ointment before the insertion of a central venous catheter for parenteral nutrition. Eight hours after dermal application, his methemoglobin levels were 24.6% and was given an intravenous methylene blue infusion which promptly cleared his cyanosis and restored tissue oxygenation. The samples were analyzed for methemoglobin reductase enzyme activity. The initial enzyme activity level was 14.8 IU/g. Seven months later, the activity level of methemoglobin reductase was repeated and resulted normal (25.7 IU/g). Conclusion: We conclude that a light inadvertent miscalculation of the dose can lead to serious adverse effect, such as in our case. Because preterm neonates are easily overdosed for low weight routinely use of EMLA should be carefully evaluated. | ||
| 700 | 0 | |a Raffaela Butera |4 oth | |
| 700 | 0 | |a Felicia Varsalone |4 oth | |
| 700 | 0 | |a Federica Nociforo |4 oth | |
| 700 | 0 | |a Cristina Vercellati |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug therapy |d [S.l.] : Bentham Science, 2006 |g 12(2017), 1, Seite 73-76 |w (DE-627)527561886 |w (DE-600)2274490-3 |w (DE-576)435514210 |x 1574-8855 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g number:1 |g pages:73-76 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8855&volume=12&issue=1&spage=73 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |e 1 |h 73-76 | ||